Insmed Impresses With Pulmonary Portfolio, But Still Lacks Remedy To Turn A Profit [Seeking Alpha]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Seeking Alpha
INSM's pipeline, including the recent FDA approval of BRINSUPRI and many pre-clinical programs, underpins future growth potential in its role within pulmonary disease, for instance. Despite impressive balance sheet metrics and positive Wall Street sentiment, INSM's EBITDA margin (-218.5%) and ongoing net losses raise efficiency and sustainability concerns, in particularly due to negative operating cashflow. The risk of FDA rejections, recalls, and negative outcomes of major drug trials is a sector risk also discussed today. JHVEPhoto/iStock Editorial via Getty Images The Thesis: Keep It In a Holding Pattern To Add Biotech To a Portfolio My article today ventures into the land of biotech, presenting why Insmed Incorporated ( INSM ), a biotech stock, is a hold This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Hot Picks: Biotech stocks to watch as new drugs near market [BNN Bloomberg (Canada)]BNN Bloomberg
- Insmed (NASDAQ:INSM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $225.00 to $258.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed (INSM): Assessing Valuation After a Strong Year of Share Price Gains [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 12/9/25 - Form 4
- 12/5/25 - Form 144
- 12/5/25 - Form 4
- INSM's page on the SEC website